Persistence of Oral Tolerance to Peanut

Status Completed

Clinical Trial Summary

ITN049AD (LEAP-On) Study is a continuation of the ITN032AD LEAP Study (NCT00329784).

Peanut Allergy, a recognized public health concern, is a common and potentially life-threatening food allergy for which there is no treatment. ITN032AD (LEAP) Study evaluated whether early exposure to peanut promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema. ITN049AD (LEAP-On) Study will evaluate persistent tolerance to peanut by assessing the effect of twelve months of cessation of peanut consumption in LEAP Study participants who consumed peanut and those who avoided peanut over the previous five years.

Clinical Trial Description

This is a two-sample comparison employing all available study participants in both arms of the LEAP (NCT00329784) study at visit 72. After obtaining informed consent, LEAP participants who are evaluable for peanut allergy at age 60 months (V60) will be enrolled into this study, the LEAP-On (NCT01366846) Study. All LEAP-On participants will avoid peanut for an additional 12 months regardless of their previous allocation to the LEAP Study consumption arm (Group A) or the LEAP Study avoidance arm (Group B).

At V72, after 12 months of this new intervention, all participants will have skin prick testing (SPT), specific IgE and a repeat oral challenge to peanut to determine the frequency of peanut allergy in both groups. The LEAP Study decision table will be used to determine the presence of peanut allergy. Briefly, peanut allergy will be based on the presence of a positive oral peanut challenge with objective signs of allergy. Tolerance will be established on the basis of a negative oral peanut challenge (tolerating 5 g of peanut protein in the absence of symptoms). For participants who do not have an oral challenge or an oral challenge at V72 with a determinate outcome, the following criteria will be used to determine their outcome at V72:

- If the participant is tolerant and has an IgE > 0.1 and/or SPT > 0 mm at V60, the participant will be considered non-evaluable and will not be included in the analysis.

- For all other participants, the V60 outcome will be applied to the V72 outcome (last observation carried forward).

Predictive values of peanut-specific IgE and/or SPT will not be used in the LEAP-On study because participants in the peanut consumption arm in the LEAP study are tolerating peanuts despite having high IgE and/or SPT. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01366846
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase	Phase 2
Start date	December 2012
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03089476` - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy	N/A
Recruiting	`NCT05839405` - Food Allergy in the Brain
Completed	`NCT02552537` - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions	Phase 4
Completed	`NCT01634737` - Crustacean Allergy and Dust Mites Sensitization	N/A
Recruiting	`NCT05521711` - TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation	N/A
Completed	`NCT05072665` - Fast Allergy Sensitivity Test	N/A
Active, not recruiting	`NCT04887441` - Allergology: Information, Data and Knowledge Organization
Recruiting	`NCT03265262` - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy	N/A
Completed	`NCT04186949` - Early Origins of Allergy and Asthma
Completed	`NCT02490007` - Pertussis Immunisation and Food Allergy
Recruiting	`NCT03151252` - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract	N/A
Completed	`NCT02159833` - Intranasal Diagnostics in Food Allergy: a Feasibility Study	N/A
Completed	`NCT02377284` - Prevention and Management of Food Allergies	N/A
Completed	`NCT02354729` - Encouraging Allergic Young Adults to Carry Epinephrine	N/A
Completed	`NCT02640560` - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish	N/A
Enrolling by invitation	`NCT06097572` - Improved Diagnostics in Food Allergy Study	N/A
Recruiting	`NCT04606615` - Skin Barrier Abnormalities and Oxidative Stress Response
Recruiting	`NCT05785299` - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy	N/A
Not yet recruiting	`NCT06112873` - Quality of Life in Food Allergy: Validation of Three Mini-questionnaires
Completed	`NCT03337802` - Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Persistence of Oral Tolerance to Peanut — LEAP-On

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms